Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: Update on pathophysiology and treatment. Surv Ophthalmol. 2013;58:103–26.

PubMed  Google Scholar 

Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82–118.

CAS  PubMed  Google Scholar 

Daruich A, Matet A, Marchionno L, De Azevedo J-D, Ambresin A, Mantel I, et al. Acute central serous chorioretinopathy: Factors influencing episode duration. RETINA. 2017;37:1905–15.

PubMed  Google Scholar 

Hanumunthadu D, Tan ACS, Singh SR, Sahu NK, Chhablani J. Management of chronic central serous chorioretinopathy. Indian J Ophthalmol. 2018;66:1704–14.

PubMed  Google Scholar 

Mrejen S, Balaratnasingam C, Kaden TR, Bottini A, Dansingani K, Bhavsar KV, et al. Long-term visual outcomes and causes of vision loss in chronic central serous chorioretinopathy. Ophthalmology. 2019;126:576–88.

PubMed  Google Scholar 

van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, et al. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770.

PubMed  Google Scholar 

Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S. Photodynamic therapy for central serous chorioretinopathy. Eye (Lond). 2014;28:944–57.

CAS  PubMed  Google Scholar 

Yadav NK, Jayadev C, Mohan A, Vijayan P, Battu R, Dabir S, et al. Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: Safety profile and treatment outcome. Eye. 2015;29:258–65.

CAS  PubMed  Google Scholar 

Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol. 1984;68:815–20.

CAS  PubMed  Google Scholar 

Brancato R, Scialdone A, Pece A, Coscas G, Binaghi M. Eight-year follow-up of central serous chorioretinopathy with and without laser treatment. Graefes Arch Clin Exp Ophthalmol. 1987;225:166–8.

CAS  PubMed  Google Scholar 

Pitcher JD 3rd, Witkin AJ, DeCroos FC, Ho AC. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: The CONTAIN study. Br J Ophthalmol. 2015;99:848–52.

PubMed  Google Scholar 

Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): A randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:294–303.

CAS  PubMed  Google Scholar 

Chhablani J, Rani PK, Mathai A, Jalali S, Kozak I. Navigated focal laser photocoagulation for central serous chorioretinopathy. Clin Ophthalmol. 2014;8:1543–7.

PubMed  PubMed Central  Google Scholar 

van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The PLACE Trial. Ophthalmology. 2018;125:1547–55.

PubMed  Google Scholar 

Chatziralli I, Vlachodimitropoulou A, Daoula C, Vrettou C, Galani E, Theodossiadis G, et al. Eplerenone in the treatment of central serous chorioretinopathy: A review of the literature. Int J Retina Vitreous. 2018;4:33.

PubMed  PubMed Central  Google Scholar 

Russo A, Turano R, Morescalchi F, Gambicorti E, Cancarini A, Duse S, et al. Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:1141–1148.

CAS  PubMed  Google Scholar 

Arora S, Sridharan P, Arora T, Chhabra M, Ghosh B. Subthreshold diode micropulse laser versus observation in acute central serous chorioretinopathy. Clin Exp Optom. 2019;102:79–85.

PubMed  Google Scholar 

Bae SH, Heo J, Kim C, Kim TW, Shin JY, Lee JY, et al. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Ophthalmology. 2014;121:558–65.

PubMed  Google Scholar 

Singh SR, Matet A, van Dijk EHC, Daruich A, Fauser S, Yzer S, et al. Discrepancy in current central serous chorioretinopathy classification. Br J Ophthalmol. 2019;103:737–42.

PubMed  Google Scholar 

Ravage ZB, Packo KH. Rifampin for treatment of central serous chorioretinopathy. Investig Ophthalmol Vis Sci. 2011;52:2137.

Google Scholar 

Wuarin R, Kakkassery V, Consigli A, Roquelaure D, Papanastasiou A, Schutz JS, et al. Combined Topical Anti-inflammatory and Oral Acetazolamide in the Treatment of Central Serous Chorioretinopathy. Optom Vis Sci. 2019;96:500–6.

PubMed  Google Scholar 

Golshahi A, Klingmüller D, Holz FG, Eter N. Ketoconazole in the treatment of central serous chorioretinopathy: A pilot study. Acta Ophthalmol. 2010;88:576–581.

PubMed  Google Scholar 

Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P. Interventions for central serous chorioretinopathy: A network meta-analysis. Cochrane Database Syst Rev. 2015:1–123.

Wang SK, Sun P, Tandias RM, Seto BK, Arroyo JG. Mineralocorticoid receptor antagonists in central serous chorioretinopathy: A meta-analysis of randomized controlled trials. Ophthalmol Retina. 2019;3:154–60.

CAS  PubMed  Google Scholar 

Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011;152:784–92.e782.

CAS  PubMed  Google Scholar 

Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: One-year results of a randomized controlled trial. Ophthalmology. 2008;115:1756–65.

PubMed  Google Scholar 

Semeraro F, Romano MR, Danzi P, Morescalchi F, Costagliola C. Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn J Ophthalmol. 2012;56:608–12.

CAS  PubMed  Google Scholar 

van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Blanco-Garavito R, Souied EH, et al. Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE Trial Report No. 3. Am J Ophthalmol. 2019;205:1–10.

PubMed  Google Scholar 

van Rijssen TJ, Singh SR, van Dijk EHC, Rasheed MA, Vupparaboina KK, Boon CJF, et al. Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2020;258:1191–7.

PubMed  PubMed Central  Google Scholar 

van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Dijkman G, Peters PJH, et al. Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy: The REPLACE trial. Am J Ophthalmol. 2020;216:80–9.

PubMed  Google Scholar 

Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol. 1996;114:689–92.

CAS  PubMed  Google Scholar 

Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983;95:457–66.

CAS  PubMed  Google Scholar 

Lai TYY, Staurenghi G, Lanzetta P, Holz FG, Melissa Liew SH, Desset-Brethes S, et al. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina. 2018;38:1464–77.

CAS  PubMed  Google Scholar 

Oh J, Yoon CK, Kim BH, Yu HG. Evaluation of the safety and efficacy of selective retina therapy laser treatment in patients with central serous chorioretinopathy. Korean J Ophthalmol. 2021;35:51–63.

CAS  PubMed  Google Scholar 

Kim M, Lee SC, Lee SJ. Intravitreal ranibizumab for acute central serous chorioretinopathy. Ophthalmologica. 2013;229:152–7.

CAS  PubMed  Google Scholar 

Leaver P, Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1979;63:674–7.

CAS  PubMed  Google Scholar 

Shang Q, Liu C, Wei S, Shi F, Yang A. [Wavelength selection in management of central serous chorioretinopathy]. Zhonghua Yan Ke Za Zhi. 1999;35:413–5.

CAS  PubMed  Google Scholar 

Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina. 2011;31:1928–36.

CAS  PubMed  Google Scholar 

Chrapek O, Jirkova B, Kandrnal V, Rehak J, Sin M. Treatment of central serous chorioretinopathy with beta-blocker metipranolol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159:120–3.

PubMed  Google Scholar 

Gramajo AL, Marquez GE, Torres VE, Juárez CP, Rosenstein RE, Luna JD. Therapeutic benefit of melatonin in refractory central serous chorioretinopathy. Eye (Lond). 2015;29:1036–45.

CAS  PubMed  Google Scholar 

Khosla PK, Rana SS, Tewari HK, Azad RU, Talwar D. Evaluation of visual function following argon laser photocoagulation in central serous retinopathy. Ophthalmic Surg Lasers. 1997;28:693–7.

CAS  PubMed  Google Scholar 

Ambiya V, Khodani M, Goud A, Narayanan R, Tyagi M, Rani PK, et al. Early focal laser photocoagulation in acute central serous chorioretinopathy: A prospective, randomized study. Ophthalmic Surg Lasers Imaging Retina. 2017;48:564–71.

PubMed  Google Scholar 

Boscia F, Reibaldi M, Longo A, Faro S, Uva M, Cardascia N, et al. Low fluence photodynamic therapy in chronic central serous chorioretinopathy: Blind randomised clinical trial of efficacy and safety. Investig Ophthalmol Vis Sci. 2008;49:3278.

Google Scholar 

Cheng CK, Chang CK, Peng CH. Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina. 2017;37:325–33.

CAS  PubMed  Google Scholar 

Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, et al. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015;133:333–340.

PubMed  Google Scholar 

Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol. 2010;24:155–8.

Google Scholar 

Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–36.